Single-agent PD-1 or PD-L1 inhibitors or a combination of chemotherapy and PD-1/PD-L1 inhibitors are preferred treatment options for patients with locally advanced and metastatic non-small cell lung cancer (NSCLC) without identifiable driver mutations (1). The gene discussed is CD274; the disease is non-small cell lung carcinoma.